Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003824 · ClinicalTrials.gov registry record · Phase 3

S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer

A Phase 3 study, sponsored by SWOG Cancer Research Network.

Terminated
Registry status
Phase 3
Development phase
114
Enrollment target

NCT00003824: Clinical Trial Phase 3 study, sponsored by SWOG Cancer Research Network.

NCT00003824 is a Phase 3 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 114 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003824, a Phase 3 study, was terminated before completion, sponsored by SWOG Cancer Research Network.

TERMINATED
Registry status
Phase 3
Development phase
114 participants
Enrollment target

Study Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether ciprofloxacin is more effective than cephalexin in preventing cancer recurrence in patients who are undergoing surgery to treat bladder cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of ciprofloxacin with that of cephalexin in preventing recurrence of cancer in patients who are undergoing surgery for bladder cancer.

Interventions

  • DRUG Ciprofloxacin
  • DRUG cephalexin
  • PROCEDURE surgical procedure

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 1999-04
Est. Completion 2007-01
Phase Phase 3
SWOG Cancer Research Network

270 total trials

Why NCT00003824 stopped before completion

NCT00003824 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 3 interventions - of which Ciprofloxacin is the first listed.

NCT00003824 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00003824 about?

NCT00003824 is a clinical study titled "S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether ciprofloxacin is more effective than cephalexin in preventing cancer recurrence in patients who are undergoing surgery to treat bladder cancer. PURPO...

What is the current status of trial NCT00003824?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 114 participants. The study started on 1999-04. Estimated completion is 2007-01.

What interventions are being tested in trial NCT00003824?

The interventions under investigation include: Ciprofloxacin (DRUG), cephalexin (DRUG), surgical procedure (PROCEDURE).

Who is sponsoring clinical trial NCT00003824?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00003824's enrollment target sits among peer trials

114 1648th of 2000 higher than 350 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04522791 · 114 participants · Phase 2

    Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)

  • NCT04875052 · 114 participants · NA

    Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury

  • NCT05100342 · 114 participants

    Prospective Validation of a Points Score System Predicting 30-day Survival

  • NCT05224089 · 114 participants · Phase 4

    Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00003824, the US trial registry maintained by the National Library of Medicine. NCT00003824 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.